Delapril/manidipine

Drugs

Volumn 66, Issue 7, 2006, Pages 961-969

  McCormack, Paul L ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DELAPRIL; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; MANIDIPINE; RAMIPRIL; VALSARTAN;

ANKLE EDEMA; ANTIHYPERTENSIVE ACTIVITY; ANXIETY; ANXIETY DISORDER; AREA UNDER THE CURVE; BRONCHITIS; CLINICAL TRIAL; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FATIGUE; FIRST PASS EFFECT; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; LEG EDEMA; MAXIMUM ALLOWABLE CONCENTRATION; MONOTHERAPY; NAUSEA AND VOMITING; PROTEINURIA; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; VERTIGO;

ADMINISTRATION, ORAL; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; DIHYDROPYRIDINES; DRUG COMBINATIONS; HUMANS; HYPERTENSION; INDANS; TREATMENT OUTCOME;

EID: 33744922921     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666070-00014     Document Type: Review

References (32)

1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003 May 21; 289 (19): 2560-72
2. Guidelines Committee. 2003 European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21 (6): 1011-53
3. Guidelines Sub-Committee. 1999 World Health Organization. International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999 Feb; 17 (2): 151-83
4. Gradman AH, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Current Hypertension Reports 2002; 4: 343-9
5. Taylor AA, Sunthornyothin S. The case for combining angiotensin- converting enzyme inhibitors and calcium-channel blockers. Current Hypertension Reports 1999; 1: 446-53
6. Razzetti R, Acerbi D. Pharmacokinetic and pharmacologic properties of delapril, a lipophilic nonsulfhydryl angiotensin-converting enzyme inhibitor. Am J Cardiol 1995 Jun 16; 75: 7-12F
7. Saruta T, Nishikawa K. Characteristics of a new angiotensin converting enzyme inhibitor: delapril. Am J Hypertens 1991 Jan; 4 (1 Pt 2): 23-8S
8. Cheer SM, McClellan K. Manidipine: a review of its use in hypertension. Drugs 2001; 61 (12): 1777-99
9. Fogari R, Zoppi A, Mugellini A, et al. Efficacy of delapril in the treatment of mild to moderate essential hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. Adv Ther 1997 Sep; 14: 254-61
10. Fogari R, Zoppi A, Corradi L, et al. Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. J Hypertens 2000; 18: 1871-5
11. Mugellini A, Preti P, Zoppi A, et al. Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. J Hum Hypertens 2004 Oct; 18 (10): 687-91
12. Rizzoni D, Bevilacqua M, Gobbato C, et al. Blood pressure lowering effects of delapril and manidipine, in hypertensive patients with type 2 diabetes, not adequately controlled by monotherapy [abstract no. 8.6]. High Blood Press Cardiovasc Prev 2005; 12 (3): 180
13. Onoyama K, Nanishi F, Okuda S, et al. Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (delapril) in patients with deteriorated kidney function and in normal control subjects. Clin Pharmacol Ther 1988 Mar; 43 (3): 242-9
14. Salvetti A. Newer ACE inhibitors: a look at the future. Drugs 1990 Dec; 40 (6): 800-28
15. Singlas E, Fillastre JP. Pharmacokinetics of newer drugs in patients with renal impairment (part II). Clin Pharmacokinet 1991 May; 20 (5): 389-410
16. Kelly JG, O'Malley K. Clinical pharmacokinetics of the newer ACE inhibitors: a review. Clin Pharmacokinet 1990 Sep; 19: 177-96
17. Chiesi Farmaceutici S.p.A. Summary of product characteristics (Iperten 10mg and 20mg tablets). 2006
18. Morimoto S, Matsumura Y. Manidipine hydrochloride [CV-4093 (2HCl)]. Cardiovasc Drug Rev 1991; 9 (3): 207-22
19. Deroubaix X, Lins RL, Lens S, et al. Single dose pharmacokinetics of manidipine in hepatic impaired patients and healthy controls. Int J Clin Pharmacol Ther 1998; 36 (7): 386-91
20. Stockis A, Gengler C, Goethals F, et al. Single oral dose pharmacokinetic interaction study of manidipine and delapril in healthy volunteers. Arzneimittelforschung 2003; 53 (9): 627-34
21. Stockis A, De Bruyn S, Gengler C. Pharmacokinetics and tolerability of a new manidipine and delapril fixed oral combination in young and elderly subjects. Arzneimittelforschung 2003; 53 (8): 554-61
22. Zoppi A, Mugellini A, Preti P, et al. Effects of the fixed combination of manidipine plus delapril in the treatment of hypertension inadequately controlled by monotherapy with either component: a phase III, multicenter, open-label, clinical trial. Curr Ther Res 2003 Jul; 64 (7): 422-33
23. Karpati P, Alberici M, Tocci G, et al. Long-term tolerability and efficacy of the fixed combination of manidipine and delapril in patients with essential hypertension. High Blood Press Cardiovasc Prev 2003; 10 (2): 81-6
24. Mugellini A, Vaccarella A, Celentano A, et al. Fixed combination of manidipine and delapril in the treatment of mild to moderate essential hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. Blood Press 2005 Jul 1; 14 Suppl. 1: 6-13
25. Mugellini A, Dobovisek J, Planinc D, et al. Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial. Clin Ther 2004 Sep; 26 (9): 1419-26
26. Bacchelli S, Degli Esposti D, Alberici M, et al. Effects of the combination of different doses of manidipine and delapril in hypertensive patients [abstract no. P-35]. Am J Hypertens 2002 Apr; 15 (4 Pt 2): 45-46A
27. Ambrosioni E. Clinical evaluation of manidipine-delapril combination on efficacy and tolerability in hypertensive patients [oral presentation]. New therapeutic approach for hypertension control: the rationale for the ACE inhibitor - calcium channel blocker combination (satellite symposium of the 11th European Meeting on Hypertension); 2001 Jun 15-19; Milan
28. Ambrosioni E. Manidipine and delapril in the management of hypertension. Use of a factorial design to evaluate the effects of different combinations of doses in a multicentre, controlled, randomised, double-blind clinical trial for the evaluation of the antihypertensive effect and tolerability of extemporaneous associations. (Data on file). Chiesi Farmaceutici S.p.A., 1998
29. Zannad F. Multicentre, randomised, parallel group, double-blind, double-dummy, phase III study to compare the antihypertensive effects and tolerability of delapril and manidipine monotherapy to delapril plus manidipine (CHF 1521 fixed combination) in patients with mild to moderate essential hypertension. (Data on file). Chiesi Farmaceutici S.p.A., 2004
30. Chiesi Farmaceutici S.p.A. Summary of product characteristics (Delaket 15mg and 30mg tablets). 2005
31. Fogari R, Malamani G, Derosa G, et al. Effect of delapril addition to manidipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients [abstract no. P-205]. Am J Hypertens 2003 May; 16 (5 Pt 2): 113A
32. Chiesi Farmaceutici S.p.A. Summary of product characteristics (Vivace 30mg + 10mg tablets). 2006